{"filing":{"accession_number":"0001193125-26-267640","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"d161530d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526267640/d161530d8k.htm"},"events":[{"id":5368,"run_id":4702,"accession_number":"0001193125-26-267640","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Jade Biosciences held its 2026 Annual Meeting of Stockholders with voting results on the election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6339,"accession_number":"0001193125-26-267640","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a material modification to rights of security holders via amended and restated articles of incorporation (Item 5.03). While the specific modifications are not detailed in this Item 3.03 excerpt, amendments to articles of incorporation that materially alter shareholder rights are typically material events. However, without seeing the actual substantive changes in Item 5.03, the precise nature and materiality cannot be fully assessed, warranting moderate confidence and classification as \"other_material\" rather than a more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6340,"accession_number":"0001193125-26-267640","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This Item 5.03 discloses routine amendments to the Company's Articles of Incorporation and Bylaws, including a jury trial waiver approved by stockholders and technical/modernizing changes to align with Nevada law (virtual meetings, record date provisions, voting standards). While these are formal governance changes, they are administrative in nature and do not affect the registrant's financial condition, operations, or investor risk profile in a material way.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6341,"accession_number":"0001193125-26-267640","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete voting results from Jade Biosciences' 2026 Annual Meeting of Stockholders, including election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers. The detailed vote tallies (for, against, abstain, broker non-votes) for each matter are the hallmark of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6339,"accession_number":"0001193125-26-267640","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a material modification to rights of security holders via amended and restated articles of incorporation (Item 5.03). While the specific modifications are not detailed in this Item 3.03 excerpt, amendments to articles of incorporation that materially alter shareholder rights are typically material events. However, without seeing the actual substantive changes in Item 5.03, the precise nature and materiality cannot be fully assessed, warranting moderate confidence and classification as \"other_material\" rather than a more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-11"},{"id":6340,"accession_number":"0001193125-26-267640","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This Item 5.03 discloses routine amendments to the Company's Articles of Incorporation and Bylaws, including a jury trial waiver approved by stockholders and technical/modernizing changes to align with Nevada law (virtual meetings, record date provisions, voting standards). While these are formal governance changes, they are administrative in nature and do not affect the registrant's financial condition, operations, or investor risk profile in a material way.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-11"},{"id":6341,"accession_number":"0001193125-26-267640","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete voting results from Jade Biosciences' 2026 Annual Meeting of Stockholders, including election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers. The detailed vote tallies (for, against, abstain, broker non-votes) for each matter are the hallmark of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:30:21.076258+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-11"}]}